Aandeel IPSC CENTURY THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Century Therapeutics, Inc.

Aandelen

IPSC

US15673T1007

Beurs gesloten - Nasdaq
Andere beurzen
 22:30:01 03-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
3,03 USD +1,00% Intraday-grafiek van Century Therapeutics, Inc. +5,21% -8,73%
12/04 CENTURY THERAPEUTICS, INC. : Piper Sandler herhaalt koopadvies ZM
11/04 Syncona stemt in met verkoop belang in participatiebedrijf voor GBP7,4 miljoen AN

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Syncona agrees to sell stake in investee company for GBP7.4 million
Syncona to Sell Stake in Portfolio Company to Century Therapeutics
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Sector Update: Health Care Stocks Retreating Late Afternoon
Century Therapeutics Shares Fall After Wider Loss, Lower Revenue in 2023
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Century Therapeutics : Corporate Overview March 2024
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers IPSC
  4. Nieuws Century Therapeutics, Inc.
  5. Andere talen